• About us
• Contact

Advertisement

Organisation › Details

Merck & Co. Inc. (NYSE: MRK)

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service *

 

	Start	1990-01-01 existent
	Group	Merck (US) (MSD) (Group)
	Industry	pharmaceutical
	Person	Davis, Robert M. (Rob) (Merck (US) 202107– CEO before CFO formerly Baxter 200703 CFO)
	Street	One Merck Drive P.O. Box 100
	City	08889-0100 Whitehouse Station, NJ
		Address record changed: 2020-12-02
Basic data	Employees	I: 50,001 to 100,0 (2007-11-13)
	Currency	USD
	Annual sales	22,600,000,000 (sales (2006) 2006-12-31)
	Profit	4,433,800,000 (2006-12-31)
		* Document for »About Section«:
		Record changed: 2024-07-30

Advertisement

More documents for Merck (US) (MSD) (Group)

• [1] N-Power Medicine, Inc.. (7/1/24). "Press Release: N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials". Redwood City, CA....
• [2] N-Power Medicine, Inc.. (7/1/24). "Press Release: N-Power Medicine Emerges with Series B Funding to Bolster Access to Innovative Oncology Clinical Trials". Redwood City, CA....
• [3] Merck & Co., Inc.. (5/29/24). "Press Release: Merck to Acquire EyeBio". Rahway, NJ & New York, NY....
• [4] Owkin. (12/19/23). "Press Release: Owkin Enters Collaboration Agreement with MSD to Develop AI-powered Diagnostics for Cancer"....
• [5] Merck & Co., Inc.. (11/21/23). "Press Release: Merck to Acquire Caraway Therapeutics, Inc.". Rahway, NJ & Cambridge, MA....
• [6] Merck & Co., Inc.. (10/19/23). "Press Release: Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs". Basking Ridge, NJ & Rahway, NJ....
• [7] AiCuris Anti-infective Cures AG. (8/23/23). "Press Release: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of Prevymis (letermovir) in Second Indication". Wuppertal....
• [8] Anavo Therapeutics B.V.. (5/2/23). "Press Release: Anavo Therapeutics Extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic". Leiden & Heidelberg....
• [9] Proxygen GmbH. (4/5/23). "Press Release: Proxygen Announces Collaboration and License Agreement with MSD". Vienna....
• [10] Merck & Co., Inc.. (12/21/22). "Press Release: Lynparza (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer". Rahway, NJ....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.